Navigation Links
Verenium to Present at Upcoming Conferences
Date:9/1/2011

partnerships, target markets and future financial performance, results and objectives, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these f
'/>"/>
SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011
2. Verenium Announces Debt Repurchase
3. Verenium Announces Signing of Lease for New Office and Lab Space
4. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
5. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
6. Verenium to Present at Upcoming Conferences
7. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
8. Verenium to Present at MDB Capital Groups Bright Lights Conference
9. Verenium Announces Debt Repurchase
10. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
11. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... the Sale of Ready to Drink,Suite of Nutritional Supplements to Provider ... ... BASKING RIDGE, N.J., June 5 Millennium Biotechnologies,Inc., wholly owned subsidiary ... it has entered into an,amendment of it,s November 9th 2007 Master ...
... Compendia Bioscience today,announced that it has signed ... GSK ) for Oncomine(TM) Enterprise Edition, a,value-added ... Edition builds upon the features of Oncomine,Professional ... to securely,view proprietary gene expression data in ...
... LAWRENCE, Mass., June 5 NxStage Medical, Inc.,(Nasdaq: ... announced that Jeffrey H. Burbank, Chief Executive Officer, and,Robert ... the William,Blair 28th Annual Growth Stock Conference on June ... NxStage,s investor presentation is scheduled for Wednesday, June ...
Cached Biology Technology:Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 2Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc. 3GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2NxStage Medical to Present at William Blair Growth Stock Conference 2
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... multiple sclerosis (MS), neuroradiologists and neurologists of the University ... visualize inflammatory tissue damage, most of which had remained ... new contrast medium, Gadofluorine M, in magnetic resonance imaging. ... edition of the renowned medical journal Brain . ...
... About 4,000 children in the United States die every ... septic shock, and researchers are pushing the boundaries of ... the condition. But a simple measure of an immune ... the hospital for septic shock can predict survival in ...
... a pilot study in children with sarcoma, researchers at ... could prove beneficial in treating high-risk forms of this ... vaccine as well as a standard flu vaccine to ... findings, published in the August 1 issue of ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Immune system protein accurate predictor of survival in pediatric septic shock 2Immune system protein accurate predictor of survival in pediatric septic shock 3Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
Request Info...
Request Info...
Biology Products: